DomaniCell Cord Blood Banking Program Launched at Saint Peter's University Hospital
News Jan 11, 2008
Since its beginnings in 1907, Saint Peter's University Hospital has grown to a 478-bed teaching hospital with a full range of specialized pediatric healthcare services and one of the largest neonatal intensive care units in the country. As a state-designated acute care children's hospital, Saint Peter's offers a full range of specialized pediatric healthcare service with one of the most sophisticated maternity programs and one of the largest, most advanced neonatal intensive care units in the country.
The DomaniCell program involves hospitals partnering with DomaniCell to develop their own cord blood stem cell banking program that is built on DomaniCell infrastructure and technology.
DomaniCell's program is built upon years of clinical and industry experience gained through its parent company, Progenitor Cell Therapy LLC. Progenitor Cell Therapy's management team has over 135 years of combined experience in cell therapy, built five cGMP facilities, and participated in over 50 regulatory filings in the US and Europe.
"We are very excited about the business advantages DomaniCell is offering to its hospital partners though our turnkey solution. By launching a cord blood program with DomaniCell, Saint Peter's University Hospital has demonstrated a commitment to providing the highest quality and most advanced health-related services to its community."
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.